At a Glance
- ADMA Biologics is subject to a securities class action lawsuit.
- Allegations claim misleading statements regarding business operations and prospects.
- Investors have until July 15, 2024, to seek lead plaintiff status.
ADMA Biologics, Inc. is facing a securities class action lawsuit filed by Robbins Geller Rudman & Dowd LLP on behalf of investors. The complaint alleges that the biopharmaceutical company made materially false and misleading statements and omitted crucial information during a specified period. This legal action could significantly impact the company's financial standing and market reputation.
Allegations of Misleading Statements
The lawsuit targets ADMA Biologics, Inc. for alleged violations of federal securities laws. It claims that the company misled investors between May 17, 2021, and May 17, 2024, concerning its business, operations, and future prospects. These alleged misrepresentations reportedly caused substantial losses for investors during the class period.
Specifically, the complaint highlights issues related to ADMA's plasma collection centers. It suggests that the company failed to disclose problems with compliance with U.S. Food and Drug Administration (FDA) regulations and manufacturing processes. Such issues could significantly undermine the company's operational integrity and product viability.
The legal filing also asserts that ADMA Biologics' public statements about its financial health and operational efficiency were not fully accurate. These alleged omissions and false statements created an inflated perception of the company's value. The lawsuit seeks to recover damages for investors who purchased ADMA securities based on this purportedly misleading information.
"The complaint alleges that ADMA made materially false and misleading statements and omitted material information concerning its business, operations, and prospects."
— Robbins Geller Rudman & Dowd LLP
Investor Action and Legal Context
Investors who suffered losses after purchasing ADMA Biologics securities during the designated class period now have an opportunity to participate in the legal proceedings. The deadline for investors to move the court for appointment as lead plaintiff is July 15, 2024. This role allows a plaintiff to oversee the litigation on behalf of the entire class.
The lawsuit, titled *Kahn v. ADMA Biologics, Inc.*, has been filed in the U.S. District Court for the District of New Jersey. Similar legal challenges often arise when public companies face scrutiny over their financial disclosures, as seen in the recent Via Transportation class action lawsuit over alleged misleading statements. Such cases underscore the importance of transparent corporate communication.
Robbins Geller Rudman & Dowd LLP, a firm specializing in securities class actions, is representing the investors in this case. They encourage affected shareholders to contact them for more information regarding their rights and options. More details about the company's operations can be found on the ADMA Biologics, Inc. website.
The initiation of this class action lawsuit places ADMA Biologics under considerable legal and financial pressure. As the July 15 deadline approaches, the focus will be on the appointment of a lead plaintiff and the company's response to these significant allegations. The outcome of this case could set a precedent for corporate accountability in the biopharmaceutical sector.